Lexicon Pharmaceuticals (LXRX) Rallies on Heavy Volume After It Achieves Positive SOLOIST and SCORED Outcomes
Lexicon is heading towards a big breakthrough as the company obtains key primary endpoints in phase 3 of both the SOLOIST and SCORED studies. Lexicon